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solely in Mz-Ch-1 as compared to KMCH-1. Moreover, PLK inhibition decreases protein levels of Bcl-2;
an effect that can be reversed by the proteasomal degradation inhibitor MG-132. In contrast, protein
levels of Bax were not found to be altered by PLK inhibition. These findings indicate that cytotoxic
effects of Cisplatin in Mz-Ch-1 cells can be enhanced by cotreatment with BI6727. CONCLUSION In
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Bcl-2 degradation as an additional pro-apoptotic effect.
DOI: https://doi.org/10.3748/wjg.v23.i22.4007
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-145560
Published Version
 
 
Originally published at:
Sydor, Svenja; Jafoui, Sami; Wingerter, Lena; Swoboda, Sandra; Mertens, Joachim C; Gerken, Guido;
Canbay, Ali; Paul, Andreas; Fingas, Christian D (2017). Bcl-2 degradation is an additional pro-apoptotic
effect of polo-like kinase inhibition in cholangiocarcinoma cells. World Journal of Gastroenterology,
23(22):4007-4015.
DOI: https://doi.org/10.3748/wjg.v23.i22.4007
Svenja Sydor, Sami Jafoui, Lena Wingerter, Guido Gerken, 
Ali Canbay, Department of Gastroenterology and Hepatology, 
University Hospital Essen, University Duisburg-Essen, 45122 
Essen, Germany
Sandra Swoboda, Andreas Paul, Christian D Fingas, 
Department for General, Visceral and Transplantation Surgery, 
University Hospital Essen, University Duisburg-Essen, 45122 
Essen, Germany
Joachim C Mertens, Division of Gastroenterology and Hepa-
tology, University Hospital Zurich, 8091 Zurich, Switzerland
Author contributions: Sydor S contributed to acquisition, 
analysis and interpretation of data, statistical analysis, drafting 
of the manuscript; Jafoui S contributed to acquisition and 
analysis of data; Wingerter L contributed to acquisition and 
analysis of data; Swoboda S contributed to acquisition and 
analysis of data; Mertens JC contributed to critical revision 
of the manuscript for important intellectual content, technical 
support; Gerken G contributed to obtained funding, critical 
revision of the manuscript for important intellectual content; 
Canbay A contributed to obtained funding, critical revision of the 
manuscript for important intellectual content; Paul A contributed 
to obtained funding, critical revision of the manuscript for 
important intellectual content; Fingas CD contributed to study 
concept and design.
Supported by DFG/German Research Foundation, No. FI 
1630/3-1 and No. IFORES D/107-114400 (to CDF). 
Institutional review board statement: For this study no human 
or animal derived material was used. All performed experiments 
and shown data were assessed by using established cell lines and 
were performed according to good laboratory practice guidelines. 
The study was reviewed and approved by the University of 
Duisburg-Essen Institutional Review Board.
Institutional animal care and use committee statement: 
For this study we did not perform animal experiments or use 
experimental material derived from animals. Provision of an 
institutional animal care and use committee statement is not 
applicable in this case. 
Conflict-of-interest statement: The authors have no conflicts of 
interest.
Data sharing statement: There are no additional data available. 
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Invited manuscript
Correspondence to: Christian D Fingas, MD, PhD, Associate 
Professor, Department for General, Visceral and Transplantation 
Surgery, University Hospital Essen, University Duisburg-Essen, 
Hufelandstraße 55, 45122 Essen, 
Germany. christian.fingas@uk-essen.de
Telephone: +49-201-723 83676 
Fax: +49-201-7231131
Received: January 13, 2017  
Peer-review started: January 14, 2017
First decision: February 23, 2017
Revised: April 5, 2017 
Accepted: May 9, 2017  
Article in press: May 9, 2017
Published online: June 14, 2017
Abstract 
AIM
To examine the influence on apoptotic mechanisms 
following inhibition of polo-like kinases as therapeutically 
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ORIGINAL ARTICLE
Bcl-2 degradation is an additional pro-apoptotic effect of 
polo-like kinase inhibition in cholangiocarcinoma cells
Basic Study
Svenja Sydor, Sami Jafoui, Lena Wingerter, Sandra Swoboda, Joachim C Mertens, Guido Gerken, Ali Canbay, 
Andreas Paul, Christian D Fingas
approach for cholangiocellular cancer treatment. 
METHODS
As most cholangiocarcinomas are chemotherapy-
resistant due to mechanisms preventing tumor cell 
death, we investigated the effect of Cisplatin on 
cholangiocellular carcinoma (CCA) cell lines KMCH-1 
and Mz-Ch-1. Polo-like kinases (PLK) are important 
regulators of the cell cycle and their inhibition is 
discussed as a potential therapy while PLK inhibition 
can regulate apoptotic mediators. Here, cells were 
treated with PLK inhibitor BI6727 (Volasertib), Cisplatin, 
and in combination of both compounds. Cell viability 
was assessed by MTT; apoptosis was measured by 
DAPI staining and caspase-3/-7 assay. Western blot 
and qRT-PCR were used to measure expression levels 
of apoptosis-related molecules Bax and Bcl-2. 
RESULTS
The cell viability in the CCA cell lines KMCH-1 and 
Mz-Ch-1 was reduced in all treatment conditions 
compared to vehicle-treated cells. Co-treatment 
with BI6727 and cisplatin could even enhance the 
cytotoxic effect of cisplatin single treatment. Thus, 
co-treatment of cisplatin with BI6727 could slightly 
enhance the cytotoxic effect of the cisplatin in both 
cell lines whereas there was evidence of increased 
apoptosis induction solely in Mz-Ch-1 as compared to 
KMCH-1. Moreover, PLK inhibition decreases protein 
levels of Bcl-2; an effect that can be reversed by the 
proteasomal degradation inhibitor MG-132. In contrast, 
protein levels of Bax were not found to be altered by 
PLK inhibition. These findings indicate that cytotoxic 
effects of Cisplatin in Mz-Ch-1 cells can be enhanced by 
co-treatment with BI6727.
CONCLUSION
In conclusion, BI6727 treatment can sensitize CCA cells 
to cisplatin-induced apoptosis with proteasomal Bcl-2 
degradation as an additional pro-apoptotic effect.
Key words: Tumor necrosis factor-related apoptosis-
inducing ligand; Myeloid cell leukemia-1; Hedgehog 
pathway; Cisplatin; Chemotherapy resistance
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This manuscript addresses the timely and 
topical roles of cell cycle/apoptosis modulating enzymes 
for the tumor biology of human cholangiocarcinoma. 
These data suggest that polo-like kinases -Inhibition by 
BI6727 (volasertib) sensitizes some cholangiocarcinoma 
cell lines to cisplatin-induced apoptosis. Our findings 
include an enhanced cytotoxic effect of cisplatin by 
co-treatment with BI6727 (volasertib) and results 
in decreased protein expression levels of the anti-
apoptotic molecule Bcl-2, which appears to be 
mediated via  proteasomal degradation. Taken together, 
these data reveal another pro-apoptotic mechanism 
of polo-like kinase inhibition emphasizing the potential 
therapeutic benefit of polo-like kinase inhibitors for the 
treatment of cholangiocarcinoma. 
Sydor S, Jafoui S, Wingerter L, Swoboda S, Mertens JC, 
Gerken G, Canbay A, Paul A, Fingas CD. Bcl-2 degradation is 
an additional pro-apoptotic effect of polo-like kinase inhibition 
in cholangiocarcinoma cells. World J Gastroenterol 2017; 
23(22): 4007-4015  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v23/i22/4007.htm  DOI: http://dx.doi.
org/10.3748/wjg.v23.i22.4007
INTRODUCTION
Cholangiocellular carcinoma (CCA) represents the most 
common primary liver cancer with biliary differentiation 
and its incidence is increasing constantly in Western 
countries[1-5]. Therapeutic options are limited for CCA 
as tumors can be multifocal in advanced stages being 
surgically non-accessible. Additionally, CCA is often 
resistant to conventional chemotherapy and, therefore, 
associated with poor prognosis[6]. Development and 
progression of CCA are in part mediated by mecha-
nisms that prevent tumor cell death[3,7]. For example, 
these cancer cells paradoxically express tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL) as 
well as its cognate receptors[8-10] but are quite resistant 
to TRAIL-induced apoptosis[10-13]. The underlying 
mechanisms are complex and seem to be mediated by 
effective survival signals that prevent TRAIL-induced 
apoptosis (e.g., upregulation of anti-apoptotic proteins 
of the Bcl-2 family)[8,14,15].
Polo-like kinases (PLK) represent a highly conserved 
family of several members of serine/threonine kinases 
regulating cell cycle division and are often overex-
pressed in tumor tissue of many different tumors 
including CCA[16]. PLK 1/2 expression is known to be 
associated with a poor prognosis and short overall 
survival rates in CCA[17]. PLK2 has been shown to be 
upregulated by Hedgehog (Hh) signaling - another 
important survival mechanism in CCA[8,18]. 
Thus, PLK2 appears to be an important mediator 
of Hh survival signaling as its expression is reduced 
when Hh signaling is inhibited[8]. In this context, PLK 
inhibition is discussed as a new potential therapeutical 
approach for the treatment of different cancers 
and has been described to decrease myeloid cell 
leukemia-1 (Mcl-1) - an anti-apoptotic member of 
the Bcl-2 protein family that has been identified as 
an important survival factor in CCA[15,19-21]. Members 
of the Bcl-2 family include anti- as well as pro-
apoptotic proteins. The anti-apoptotic members 
Bcl-2 and Mcl-1 can prevent apoptosis induction by 
inhibition of mitochondrial cytochrome C release while 
the pro-apoptotic protein Bax can induce apoptosis 
by stimulating cytochrome C release[22-24]. We have 
recently shown that PLK2 inhibition can decrease Mcl-1 
levels by proteasomal degradation inducing apoptosis 
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in CCA cells, which finally results in tumor suppression 
in vivo[8].
Beside gemcitabine, cisplatin is a conventional 
chemotherapeutic drug used for CCA treatment 
that can induce cell death in fast replicating cells by 
inhibition of DNA replication causing DNA damage 
and apoptosis[22,25]. However, treatment with cisplatin 
often results in chemoresistance and therapy failure[25]. 
Many different underlying mechanisms have been 
described in this context such as defective DNA binding, 
premature degradation, and increased activation of 
specific transporter proteins[25]. 
In this study, we aimed to investigate the impact of 
PLK inhibition in cisplatin-treated CCA cell lines and its 
effect on several Bcl-2 family members (beside Mcl-1) 
that might be involved in the mechanism of apoptosis 
resistance in CCA. 
MATERIALS AND METHODS
Cell culture
Human CCA cell lines KMCH-1 and Mz-Ch-1 were 
cultured in Dulbecco’s modified eagle medium/high-
glucose medium (Invitrogen, Carlsbad, CA, United 
States) containing 10% fetal bovine serum, 1000 U/mL 
Penicillin, 0.1 mg/mL streptomycin and 2 mmol/L 
L-glutamine (PAA, Pasching, Austria) at 5% CO2 and 
37 ℃. The selective PLK-inhibitor BI6727/Volasertib[26] 
(Selleckchem, Houston, TX, United States) and the 
proteasome inhibitor MG-132 (Merck, Rockland, 
MA, United States) were dissolved in DMSO (Sigma-
Aldrich, St. Louis, MO, United States), Cisplatin (Merck, 
Rockland, MA, United States) was dissolved in PBS, 
stock solutions of substances or vehicle as control 
were subsequently diluted in cell culture medium for 
experiments.
MTT cell viability assay
For assessing cell viability 5 × 104cells/well were plated 
in 96-multiwell plates. Twenty-four h after plating, cells 
were incubated with 200 nmol/L BI6727 or 1 mmol/L 
cisplatin for 24 h as described previously[8]. Cell viability 
was measured by MTT assay. The cells incubated with 
vehicle (DMSO) for 24 h were considered 100% viable.
Quantitation of apoptosis
Apoptosis in CCA cells was quantified by assessing 
characteristic nuclear changes of apoptosis after staining 
with 4’, 6-diamino-2-phenylindole dihydrochloride (DAPI; 
Sigma-Aldrich, St. Louis, MO, United States) using 
fluorescence microscopy as described previously[27]. 
Caspase-3/-7 activity was assessed by Caspas-3/-7 
assay (Promega, Madison, WI, United States) according 
to manufacturer’s recommendations. 
RNA isolation and qRT-PCR
Cells were seeded at a density of approx. 1 × 106 
cells/cm2 for in vitro experiments. At the end of the 
stimulation period total RNA extraction and purification 
was performed using RNeasy Mini Kit (Qiagen, Hilden, 
Germany) following manufacturer instructions. Reverse 
transcription was performed with the QuantiTect RT 
kit (Qiagen; Hilden, Germany) using 1 μg of total 
RNA. Quantitative realtime PCR (qRT-PCR) for specific 
mRNA sequences was performed on a CFX96 Touch 
Real-Time PCR Detection System (Bio-Rad, Hercules, 
CA, United States) using QuantiTect SYBR Green Kit 
(Qiagen, Hilden, Germany) in a final volume of 15 μL 
including 2 μL of cDNA. Oligonucleotide sequences 
for Bax primers were used as follows: Bax forward: 
5’-TCTGACGGCAACTTCAACTG-3’; Bax reverse: 
5’-GGAGGAAGTCCAATGTCCAG-3’. Melting curves 
were collected to ascertain specificity of PCR products. 
Changes in mRNA expression were calculated by 
the ΔΔ-ct method and are presented as foldchan-
ges in relation to expression of a reference gene 
(hypoxanthine-guanine phosphoribosyltransferase, 
HPRT) in vehicle-treated cells.
Protein isolation and western blot
Cells were seeded at a density of approx. 1 × 106 
cells/cm2 for in vitro experiments, at the end of the 
stimulation period protein lysates were prepared 
using lysis buffer (50 mmol/L Tris-HCl; 150 nmol/L 
NaCl; 0.1% NP-40; 1% desoxycholic acid) containing 
complete mini EDTA-free protease inhibitor cocktail 
and phosphostop (Roche, Mannheim, Germany). 
In all, 30 μg of total protein were separated using 
SDS-PAGE, immunoblotting was performed using 
standard procedures with the following primary 
antibodies (incubation: overnight at 4 C): Actin 
(1/1000; #5125; Cell Signaling, Cambridge, United 
Kingdom), Bax (1/1000; #2772; Cell Signaling) and 
Bcl-2 (1/1000; #2876; Cell Signaling), cleaved PARP 
(1/1000; #5625, Cell Signaling). After incubation with 
the appropriate horseradish peroxidase-conjugated 
secondary antibody, bound antibodies were visualized 
using chemiluminescence reagent ECL-Prime reagent 
(GE Healthcare, Chalfont St. Giles, United Kingdom) 
according to the supplier’s protocol. Blotting images 
and densitometric quantification of protein bands was 
generated using Fusion detection system (PeqLab 
Biotechnology, Erlangen, Germany). 
Statistical analysis
Statistical significance for in vitro experiments was 
determined by one-way ANOVA (with Tukey’s post-
hoc test for individual experimental conditions) and by 
a two-tailed unpaired Student t test performed with 
Prism 5 (GraphPad Software, Inc.; San Diego, CA, 
United States). Data are presented as mean ± SEM. 
Differences were considered significant at p < 0.05.
RESULTS
Cytotoxic effects of cisplatin are enhanced by co-
treatment with PLK inhibitor BI6727
In previous studies, we demonstrated that the PLK 
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repair and replication processes[29]. In KMCH-1 cells 
PARP cleavage was not detected (data not shown) 
while in Mz-Ch-1 cells, protein levels of cleaved PARP 
were slightly induced after BI6727 single treatment 
and cisplatin/BI6727 combination treatment (Figure 
2A and B).
Thus, co-treatment of cisplatin with the PLK-
inhibitor BI6727 could (slightly) enhance the cytotoxic 
effect of the cytostatic drug cisplatin in both cell lines 
whereas there was evidence of increased apoptosis 
induction solely in Mz-Ch-1 cells as compared to 
KMCH-1 cells. 
PLK Inhibition by BI6727 alters Bcl-2 but not Bax 
expression
As shown previously, pro-apoptotic effects of 
BI6727 treatment are in part mediated by Mcl-1 
down regulation[8]. As other important regulators of 
apoptosis, we here aimed to investigate the effect 
of BI6727 on the anti-apoptotic protein Bcl-2 as well 
as the pro-apoptotic Bcl-2 family member Bax. We 
determined Bax mRNA expression levels in KMCH-1 
and Mz-Ch-1 cells by qRT-PCR treated with BI6727, 
cisplatin or both substances. In KMCH-1 cells, BI6727 
treatment induced Bax expression and this effect 
was also present in cells co-treated with BI6727 and 
cisplatin. Interestingly, cisplatin as a single agent did 
not induce Bax expression (Figure 3A). In contrast, Bax 
protein levels, determined via western blot analysis 
and quantified by densitometric measurement, were 
not changed in KMCH-1 cells treated with BI6727 
and/or cisplatin (Figure 3B and C). In Mz-Ch-1 cells, 
Bax expression was significantly induced by cisplatin 
treatment whereas BI6727 treatment had no effect 
on Bax. Following combination treatment of BI6727 
with cisplatin, Bax was not further induced (Figure 
3D). Western blot analyses did not show alterations 
regarding the Bax expression levels in Mz-Ch-1 cells 
after treatment with one of the components or after 
combination treatment (Figure 3E and F).
In Mz-Ch-1 cells, protein levels of Bcl-2 were 
reduced after treatment with cisplatin single treatment, 
cisplatin/BI6727 combination treatment, and especially 
BI6727 single treatment (Figure 3G and H). To assess 
whether the Bcl-2 decrease is a result of proteasomal 
degradation, cells were co-treated with the potent 
proteasome inhibitor MG-132. Indeed, inhibition of 
proteasomal degradation by co-treatment of BI6727 
with MG-132 restored Bcl-2 to normal levels similar to 
the vehicle control.
Thus, PLK inhibition reduces Bcl-2 protein levels in a 
posttranslational manner by proteasomal degradation 
resulting in enhanced apoptosis (Figure 3G and H).
DISCUSSION
This study reveals an additional pro-apoptotic effect 
of polo-like kinase inhibition in CCA cell lines. The 
inhibitor BI6727 had a pro-apoptotic effect in CCA 
cell lines and could exacerbate TRAIL-induced cell 
death[8]. Cisplatin is one of the conventional cytostatic 
drugs that are used for the chemotherapy of CCA. 
Here, we aimed to further investigate the effect of 
the PLK inhibitor BI6727 on cell death in CCA cell 
lines in the presence or absence of cisplatin. We 
measured viability in the CCA cell lines KMCH-1 and 
Mz-ChA-1 treated with cisplatin and BI6727 for 24 h 
via a MTT viability assay. Cell viability was reduced 
in all treatment conditions compared to vehicle-
treated KMCH-1 (Figure 1A) and Mz-Ch-1 cells (Figure 
1D). Co-treatment with BI6727 and cisplatin could 
even enhance the cytotoxic effect of cisplatin single 
treatment. By means of the MTT viability assay, we 
could demonstrate that cell viability was reduced 
under different treatment conditions in these two cell 
lines; however, with this assay the type of cell death 
cannot be determined. To assess apoptosis induction 
caused by the different treatments, we performed 
DAPI staining with quantitation of apoptotic nuclei 
by fluorescence microscopy as well as fluorescent 
analysis of caspase-3/-7 activity. In KMCH-1 cells 
treated with BI6727, cisplatin and the combination 
of BI6727 and cisplatin, some apoptotic nuclei were 
found (Figure 1B). Moreover, caspase-3/-7 activity was 
slightly induced in BI6727-treated KMCH-1 cells (Figure 
1C). In KMCH-1 cells treated with the cytotoxic drug 
cisplatin, caspase-3/-7 activity was reduced compared 
to vehicle-treated cells whereas co-treatment with 
BI6727 and cisplatin induced caspase -3/-7 activitiy 
as compared to cisplatin only-treated cells. In KMCH-1 
cells, viability was reduced by treatment with BI6727 
or cisplatin and the combination of BI6727 with 
cisplatin could even exacerbate this effect (which does 
not appear to be mediated by apoptosis induction). 
In Mz-Ch-1 cells, we could observe a similar effect 
as co-treatment of BI6727 and cisplatin could 
slightly enhance the cytotoxic effect of both single 
agents (Figure 1D). Quantification of apoptotic nuclei 
demonstrated that BI6727 or cisplatin treatment 
increased the number of apoptotic nuclei. The number 
of apoptotic nuclei was increased in BI6727-treated 
cells as compared to cisplatin-treated cells while 
the combination of these substances enhanced the 
apoptotic effect of cisplatin single treatment (Figure 
1E). Caspase-3/-7 activity was induced in BI6727-
treated as compared to vehicle-treated cells whereas 
cisplatin treatment did not enhance caspase activity 
(Figure 1F). Under co-treatment conditions with 
BI6727 and cisplatin, caspase-3/-7 activity could 
be stronger induced as compared to cisplatin single 
treatment. In order to confirm apoptosis induction we 
also checked cleavage of the chromatin-associated 
enzyme PARP [poly (ADP-ribose) polymerase 1]. PARP 
is involved in DNA repair and replication but PARP 
cleavage has been described to be an early event 
during apoptosis[28] while cleavage may diminish DNA-
Sydor S et al . Bcl-2 degradation/polo-like kinase inhibition in CCA cells
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findings indicate that the cytotoxic effect of cisplatin 
can be enhanced by co-treatment with the PLK 
inhibitor BI6727 and that PLK inhibition (beside Mcl-1) 
decreases Bcl-2 via its proteasomal degradation[8].
Cholangiocellular carcinoma represents a deadly 
disease with rising prevalence in Western countries 
and its pathogenesis is understood insufficiently. 
Effective treatment options are still rare due to missing 
understanding of pathogenic mechanisms. TRAIL has 
been discussed as an effective agent to target tumor 
cell growth and to support existing therapy options in 
different types of cancers[30-32]. However CCA tumor 
cells already express TRAIL and its cognate receptor 
in vivo but are resistant to TRAIL[14]. Many other 
pathways and factors regulating cell growth, migration 
and invasion have become potential targets in cancer 
therapy, such as the Wnt, Notch or Hh pathway (which 
has already been associated to PLK)[8,33-35]. Various 
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specific inhibitors are tested in different studies for 
their usability as potent anti-cancer drugs or additives 
to existing therapies[8,36]. The potent PLK inhibitor 
BI6727 (volasertib) has been identified as a promising 
candidate for cancer therapy as PLK are upregulated 
in many different cancers[16,17,37-39]. PLK depletion in 
different stromal cancer cells using small interfering 
RNA technique resulted in cell cycle arrest and 
increased apoptosis[38]. Using KMCH-1 and Mz-Ch-1 
CCA cancer cells, we here could demonstrate increased 
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Figure 3  Impact of treatment with BI6727 and cisplatin on Bax and Bcl-2 expression in cholangiocellular carcinoma cell lines. Bax expression levels were 
determined in KMCH-1 (A-C) and Mz-Ch-1 (D-F) cells after treatment with BI6727 (200 nmol/L for 24 h), cisplatin (1 mmol/L for 24 h) or the combination of both 
components. Bax mRNA levels were measured by qRT-PCR (A, D; mean ± SEM, n =  3), shown as foldchange compared to vehicle-treated cells. Representative 
Western blot images of Bax and the loading control actin are shown in panels B and E. Bcl-2 protein levels were determined using Western blot analysis in treated Mz-
Ch-1 cells. Proteasomal degradation was inhibited by co-treatment with MG-132 (1 μmol/L for 24 h) (G, H). Protein levels were quantified by densitometry, normalized 
to the loading control and shown as foldchange compared to vehicle-treated cells (C, F, H, mean ± SEM, n = 3); P-values were determined using student t-test. CCA: 
Cholangiocarcinoma; Bcl-2; B-cell lymphoma 2.
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overall cell death and enhanced apoptosis induction 
following treatment with the PLK-inhibitor BI6727. In 
combination with the conventional chemotherapeutic 
drug cisplatin, BI6727 could even (slightly) enhance 
cell death in KMCH-1 and Mz-Ch-1 cells whereas the 
pro-apoptotic effect was more potent in Mz-Ch-1 as 
compared to KMCH-1 cells. It is well known that PLK 
inhibition has an impact on regulation of proteins 
belonging to the Bcl-2 family as PLK inhibition 
decreases protein levels of Mcl-1 in esophageal 
squamous cell carcinomas and osteosarcomas as well 
as in KMCH-1 cells[8,38,40]. Here, we focused on the 
effect of BI6727 on the pro-apoptotic protein Bax and 
the anti-apoptotic molecule Bcl-2. Bax mRNA levels 
were slightly induced in KMCH-1 and Mz-Ch-1 cells 
treated with BI6727 and cisplatin, whereas Bax protein 
levels were not found to be changed in both cell lines. 
Moreover, Bcl-2 levels were decreased in Mz-Ch-1 cells 
treated with BI6727 (and cisplatin). This effect was not 
enhanced after combination of both components. In 
a previous study we could demonstrate that BI6727 
treatment reduced Mcl-1 levels but not Bcl-2 levels 
after 8 h of incubation[8]. In the present study we 
observed a significant reduction of Bcl-2 protein levels 
due to a longer incubation period with BI6727 of 24 h.
Thus, the pro-apoptotic effect of BI6727 treatment 
appears to be mediated by proteasomal degradation 
not only of Mcl-1 but also of the anti-apoptotic 
protein Bcl-2 (without affecting Bax protein levels). 
Overexpression of Bcl-2 is common in many types of 
human cancer and has been correlated with decreased 
susceptibility to chemotherapeutical drugs[22]. However, 
in CCA, Mcl-1 plays a more pivotal role as tumor cell 
survival factor than Bcl-2[19,41]. 
Treatment of CCA cells with the PLK inhibitor 
BI6727 beside Mcl-1[8] decreases Bcl-2 protein levels 
thereby reducing cell viability and enhancing apoptosis. 
In combination with the chemotherapeutical drug 
cisplatin, BI6727 treatment could even enhance the 
cytotoxic effect of cisplatin single treatment.
In conclusion, BI6727 treatment sensitizes some 
CCA cell lines to cisplatin-induced apoptosis with 
proteasomal Bcl-2 degradation as an additional pro-
apoptotic effect.
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